Scholarlink

<p>Chronic kidney disease (CKD) and renal allograft failure represent escalating global health burdens characterized by progressive tissue remodeling. Although interstitial fibrosis and tubular atrophy (IF/TA) are the primary determinants of long-term prognosis, their assessment currently relies on invasive kidney biopsies, which are unsuitable for longitudinal monitoring. Here, we identify soluble T-cell immunoglobulin and mucin domain-containing protein 3 (sTIM-3) as a robust, non-invasive indicator of renal histopathology and clinical outcomes. In this multi-cohort study, we enrolled 256 kidney transplant recipients (KTRs) with allograft biopsies, 442 native CKD patients with biopsy-confirmed diagnoses, and 44 KTRs with longitudinal follow-up. Pre-biopsy plasma sTIM-3 levels were quantified by ELISA and analyzed for associations with renal function, histopathological parameters, and adverse outcomes. We found that elevated sTIM-3 levels consistently correlated with impaired renal function across diverse etiologies. Notably, post-transplantation sTIM-3 exhibited slower decline kinetics compared to estimated glomerular filtration rate (eGFR), suggesting that it may reflect active tissue remodeling rather than transient functional shifts. Histopathological analyses revealed that sTIM-3 levels increased progressively with IF/TA severity, demonstrating good discriminative capacity for moderate-to-severe fibrosis. Furthermore, in KTRs, elevated sTIM-3 predicted both allograft failure and rapid eGFR decline, with its prognostic value for the latter persisting after adjustment for eGFR and urine protein. Collectively, these findings establish sTIM-3 as a non-invasive biomarker reflecting tubulointerstitial fibrosis and adverse outcomes across diverse kidney disease settings, offering complementary information to conventional functional markers.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Unlocking the roles of plasma soluble T-cell immunoglobulin and mucin domain-containing protein 3 in kidney diseases: findings from native and allograft biopsy cohorts

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月27日

查看全文
  • Yamei Li,
  • Hua Zhang,
  • Yangjuan Bai,
  • Huan Xu,
  • Yan Luo,
  • Dan Ye,
  • Xueqiao Wang,
  • Xingxin Gong,
  • Qu Yang,
  • Hanjing Liu,
  • Binqi Yang,
  • Zheyuan Zhang,
  • Yuxin Ye,
  • Yunfei An,
  • Xinhua Dai,
  • Lanlan Wang,
  • Yunying Shi

摘要

Chronic kidney disease (CKD) and renal allograft failure represent escalating global health burdens characterized by progressive tissue remodeling. Although interstitial fibrosis and tubular atrophy (IF/TA) are the primary determinants of long-term prognosis, their assessment currently relies on invasive kidney biopsies, which are unsuitable for longitudinal monitoring. Here, we identify soluble T-cell immunoglobulin and mucin domain-containing protein 3 (sTIM-3) as a robust, non-invasive indicator of renal histopathology and clinical outcomes. In this multi-cohort study, we enrolled 256 kidney transplant recipients (KTRs) with allograft biopsies, 442 native CKD patients with biopsy-confirmed diagnoses, and 44 KTRs with longitudinal follow-up. Pre-biopsy plasma sTIM-3 levels were quantified by ELISA and analyzed for associations with renal function, histopathological parameters, and adverse outcomes. We found that elevated sTIM-3 levels consistently correlated with impaired renal function across diverse etiologies. Notably, post-transplantation sTIM-3 exhibited slower decline kinetics compared to estimated glomerular filtration rate (eGFR), suggesting that it may reflect active tissue remodeling rather than transient functional shifts. Histopathological analyses revealed that sTIM-3 levels increased progressively with IF/TA severity, demonstrating good discriminative capacity for moderate-to-severe fibrosis. Furthermore, in KTRs, elevated sTIM-3 predicted both allograft failure and rapid eGFR decline, with its prognostic value for the latter persisting after adjustment for eGFR and urine protein. Collectively, these findings establish sTIM-3 as a non-invasive biomarker reflecting tubulointerstitial fibrosis and adverse outcomes across diverse kidney disease settings, offering complementary information to conventional functional markers.